PREPARATION OF LIPID NANOCARRIER FORMULATIONS AND CYTOTOXICITY STUDIES OF DONEPEZIL

Abstract

Objective: Our research endeavors to discover innovative formulations for the pharmaceutical component of radiopharmaceuticals, which are used to diagnose Alzheimer's disease. Our approach involves the incorporation of Donepezil, a proven active ingredient, into lipid-based nanocarrier systems. Additionally, we have conducted a comprehensive study on the cytotoxicity of Donepezil as a vital aspect of our research. Material and Method: Two distinct techniques were employed in creating nanocarrier formulations: emulsion and sonication. Malvern Zeta Sizer measurements were conducted to assess the properties of the prepared formulations. In addition, the cell proliferation kit II (XTT) was used to evaluate the cytotoxicity of the active ingredient Donepezil. Result and Discussion: Formulations with particle sizes ranging from 100-200 nm have been selected based on the results of characterization studies. Cytotoxicity assays have shown that amounts of Donepezil (50, 100, 500, 1000, 2000, and 5000 µg/ml) are biocompatible. These findings confirm the optimal formulation parameters for producing high-quality Donepezil-based pharmaceutical products. The characterization studies of the prepared formulations have shown that they have the potential to be used in the diagnosis of Alzheimer's disease.